AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Maxim Group Reiterates Buy Rating on PAVmed with $9.75 Average Price Target
ByAinvest
Sunday, Aug 17, 2025 7:08 pm ET1min read
PAVmed (PAVM) received a Buy rating from Maxim Group analyst Anthony Vendetti. Vendetti's report highlights PAVmed's recent earnings release, which reported a quarterly revenue of $6 million and a GAAP net loss of $13.31 billion. The analyst consensus rating for PAVmed is Moderate Buy with an average price target of $9.75. Vendetti's average return on recommended stocks is -26.2% and success rate is 23.84%.
PAVmed Inc. (PAVM), a diversified commercial-stage medical technology company, has received a Buy rating from Maxim Group analyst Anthony Vendetti. The analyst's report highlights PAVmed's recent earnings release, which reported a quarterly revenue of $6 million and a GAAP net loss of $13.31 billion. Vendetti's rating comes with an average price target of $9.75, positioning PAVmed as a moderate buy with a consensus rating of Moderate Buy.The analyst's report also notes that Vendetti's average return on recommended stocks is -26.2% and his success rate is 23.84%. Despite these figures, the analyst remains optimistic about PAVmed's future prospects, citing the company's recent strategic partnerships, product advancements, and expanding market opportunities.
PAVmed's recent financial performance has been marked by significant investments in its subsidiary Lucid Diagnostics Inc. (LUCD), which specializes in cancer prevention medical diagnostics. Lucid Diagnostics has seen a notable increase in test volumes and revenue, with a record 4,042 EsoGuard tests processed in the fourth quarter of 2024, representing a 45% sequential and 84% annual increase [24].
The company has also secured several strategic partnerships and commercial insurance coverage policies for its innovative products, such as the EsoGuard® Esophageal DNA Test. These developments indicate a growing market acceptance and potential for increased revenue streams in the future.
In summary, while PAVmed's recent earnings report shows a significant net loss, the analyst's Buy rating reflects optimism about the company's long-term potential. The report underscores the importance of strategic investments, product innovation, and market expansion in driving future growth and profitability.
References:
[1] https://ir.pavmed.com/press-releases?l=50
[24] https://ir.pavmed.com/press-releases/l=50
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet